Figure 8

Effect of simultaneous treatments on behavior in Fmr1 KO mice. (A) Sample traces of locomotor activity in the open-field test for control, SKF81297, or/and DL-AP3 injected WT or Fmr1 KO mice, respectively. (B) Fmr1 KO mice traveled more than WT mice at basal condition (n = 7 mice for WT, n = 7 mice for Fmr1 KO). SKF81297 (1 mg/kg body weight, injected subcutaneously) significantly reduced the distance traveled by Fmr1 KO mice (n = 6 mice for control, n = 8 mice for SKF81297). DL-AP3 (4 mg/kg) did not affect locomotor activity in Fmr1 KO mice; however, DL-AP3 combining SKF81297 significantly reduced the distance traveled in a larger scale as compared with the SKF81297 injection alone (n = 7 mice). SKF81297 or/and DL-AP3 did not affect locomotor activity in WT mice. (C) Time in the open arms had no differences between Fmr1 KO and WT mice in the mice treated with SKF81297 (1 mg/kg) alone or plus DL-AP3 (4 mg/kg). (D) Open arm entries had no differences between Fmr1 KO and WT mice in the mice treated with SKF81297 (1 mg/kg) alone or plus DL-AP3 (4 mg/kg). N = 6 mice in each group. (E) Simultaneous treatment of SKF81297 (1 mg/kg) alone or plus DL-AP3 (4 mg/kg) reduced the swim latency on the final day in the Fmr1 KO mice. N = 6 mice in each group. * p < 0.05, ** p < 0.01 compared with Fmr1 WT mice. # p < 0.05 compared between the mice treated with SKF81297 and DL-AP3 + SKF81297 in Fmr1 KO mice.